GE Healthcare Bets Big on Boston: Opens Life Sciences North American Headquarters to Accelerate Precision Medicine
June 23 2016 - 10:45AM
Business Wire
500-strong Marlborough, MA site a $27M commitment to
biopharmaceutical innovation and growth ahead of GE’s Corporate
headquarters move to Boston
GE Healthcare’s Life Sciences business, a global provider of
technologies and expertise to the biopharmaceutical and life
sciences industries, today opened its new 210,000 square-foot North
American headquarters in Marlborough, Massachusetts. At full
capacity in 2017, it will employ more than 500 scientists and
professionals in the Boston area focused on accelerating precision
medicine across a portfolio including:
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160623005035/en/
100 Results Way Forum (Photo: Business
Wire)
- Manufacturing technologies for cell and
immune therapies that are showing the potential to cure some of the
world’s toughest diseases, such as cancer
- Early stage research tools used to
develop the next generation of precision medicines
- Technologies and consumables for
manufacturing vaccines, insulin and the rapidly growing new class
of drugs known as biologics
- Leading-edge contrast agents and
nuclear medicine tracers that clinicians use to diagnose
disease
The new facility at 100 Results Way will be home to 40,000
square feet of laboratories supporting cell and immune therapy
research and development, early stage drug development,
biomanufacturing, as well as scientific and medical affairs
support.
The laboratories will house GE’s ninth global Fast Trak
facility, which partners with and trains biotech innovators to
discover new drugs, develop manufacturing workflows, and optimize
their biomanufacturing processes. In 2017, the site will also
include GE’s FlexFactory manufacturing platform, originally
designed in Marlborough, MA, and which pioneered end-to-end,
flexible, small batch biologic drug manufacturing.
"General Electric's ongoing investment in Massachusetts is just
the latest proof that the Commonwealth is a global leader in life
science innovation, from discovery to manufacturing and
commercialization," said Governor Charlie Baker. "With a deep bench
of talent and supportive economic environment, we are excited to
have GE Healthcare be a part of Central Massachusetts' growing
workforce and look forward to the advances that will benefit the
health and wellbeing of our citizens."
GE Healthcare’s nearby Westborough, MA, facility will continue
to produce single-use products and consumables for
biopharmaceutical manufacturing and with GE’s corporate
headquarters moving to Boston this summer, by the end of 2016, GE
will have nearly 5,000 employees across Massachusetts.
“Two years ago, we began to move our east coast North American
operations to the Boston area to better coordinate our focus on
patients, clinicians and customers’ needs,” said Kieran Murphy,
president and CEO of GE Healthcare’s Life Sciences business.
“Having our North American headquarters in the heart of
Massachusetts’ rich ecosystem of healthcare, pharma, and biotech
brings us closer to key customers, outstanding talent and
ground-breaking innovation and is already helping fuel further
growth for our business.”
###
About GE Healthcare
GE Healthcare provides transformational medical technologies and
services to meet the demand for increased access, enhanced quality
and more affordable healthcare around the world. GE (NYSE: GE)
works on things that matter - great people and technologies taking
on tough challenges. From medical imaging, software & IT,
patient monitoring and diagnostics to drug discovery,
biopharmaceutical manufacturing technologies and performance
improvement solutions, GE Healthcare helps medical professionals
deliver great healthcare to their patients. For more information
about GE Healthcare, visit our website at www.gehealthcare.com.
About GE Healthcare Life Sciences
GE Healthcare's $4B Life Sciences business is on a mission is to
accelerate an age of molecular and precision medicine by providing
expertise, tools and solutions for a wide range of applications,
including basic research of cells and proteins, drug discovery,
cell therapy and regenerative medicine, as well as tools and
technology to support large-scale manufacturing of
biopharmaceuticals, vaccines and biologics such as insulin. It also
supplies leading contrast, PET and nuclear medicine agents for
diagnostic imaging to help doctors make more informed diagnoses for
better patient outcomes. The company's mission is to help enable a
new era of molecular and precision medicine by providing customers
with the tools, insight and knowledge to guide them ever more
quickly from better biological understanding to better clinical
therapies.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160623005035/en/
GE HealthcareErin Bryant+1.203.450.5326Erin.Bryant@ge.com
GE Aerospace (NYSE:GE)
Historical Stock Chart
From Mar 2024 to Apr 2024
GE Aerospace (NYSE:GE)
Historical Stock Chart
From Apr 2023 to Apr 2024